Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

NCT01826214 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukemias

Interventions

DRUG: LDE225

Sponsor

Novartis Pharmaceuticals